Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBT (2023 - 2026)

Rallybio's EBT history spans 3 years, with the latest figure at -$5.9 million for Q4 2025.

  • On a quarterly basis, EBT rose 44.87% to -$5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.1 million, a 85.41% increase, with the full-year FY2025 number at -$8.1 million, up 85.41% from a year prior.
  • EBT hit -$5.9 million in Q4 2025 for Rallybio, down from $16.0 million in the prior quarter.
  • Over the last five years, EBT for RLYB hit a ceiling of $16.0 million in Q3 2025 and a floor of -$19.6 million in Q4 2023.
  • Historically, EBT has averaged -$11.3 million across 3 years, with a median of -$13.3 million in 2024.
  • Biggest five-year swings in EBT: fell 9.48% in 2024 and later surged 247.9% in 2025.
  • Tracing RLYB's EBT over 3 years: stood at -$19.6 million in 2023, then surged by 45.93% to -$10.6 million in 2024, then surged by 44.87% to -$5.9 million in 2025.
  • Business Quant data shows EBT for RLYB at -$5.9 million in Q4 2025, $16.0 million in Q3 2025, and -$9.4 million in Q2 2025.